Business Wire

ADVA

9.7.2020 09:02:08 CEST | Business Wire | Press release

Share
KCOM extends high-speed connectivity with ADVA’s packet edge solution

ADVA (FSE: ADV) today announced that KCOM has deployed its packet edge technology to support the extended rollout of super-fast full fiber broadband. Using the compact ADVA FSP 150 demarcation and aggregation device, the UK-based communication and IT service provider is delivering its gigabit-speed Lightstream services to tens of thousands more business and residential customers in the Yorkshire and Lincolnshire area. The high-density MEF 3.0-certified technology enables KCOM to smoothly transition from 1Gbit/s to 10Gbit/s services in its access network. ADVA’s packet edge solution also ensures that the new infrastructure is ready for 5G mobile services and can easily scale to 200Gbit/s.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005034/en/

“Our Lightstream service has already had a huge impact on businesses and in homes across this region. Now, ADVA’s technology is empowering us to go further than ever before by creating the UK’s first full-fiber city and delivering super-fast fiber connectivity to previously underserved areas,” said Tim Shaw, managing director, wholesale and networks, KCOM. “By leveraging ADVA’s packet edge device, we’ve been able to smoothly transition to 100Gbit/s capacity in our access network and aggregate lower-speed services. What makes the solution so valuable though are its extra benefits. As well as a small footprint and low power, ADVA’s packet edge technology comes with fully automated service activation. Together with its extended temperature range, this makes it simple to deploy in any environment and on a large scale.”

KCOM’s new network is built on ADVA's 100Gbit/s FSP 150 solution with MEF 3.0 Carrier Ethernet certification. The technology supports 100Gbit/s demarcation and high-scale 10Gbit/s service aggregation in an incredibly compact form factor. KCOM is managing the infrastructure with ADVA’s Ensemble Controller , a unique management system that enables programmatic SDN control. This further improves efficiency by reducing troublesome and time-consuming manual processes while providing KCOM’s maintenance team with total visibility. With its hardware-based timing and full activation testing, the solution also helps KCOM ensure the highest levels of quality and availability. What’s more, its low power consumption and ultra-compact design are key to keeping the cost of KCOM’s Lightstream services low.

“We’re proud to be supporting KCOM in this next phase of its journey. By harnessing our technology and the expertise of our team, KCOM is providing high-speed connectivity to more properties than ever before. It’s also helping to boost the economy in this region of the UK by empowering businesses to expand and seize new revenue opportunities,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our FSP 150 packet edge device features several unique advantages, such as its unique ability to verify the performance of high-bitrate services with line-rate 100Gbit/s pre-activation testing. It really is the ultimate tool for operators who need to scale their networks quickly and affordably to tackle exponential growth in data demand and lay the foundations for 5G.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About KCOM

KCOM is a leading provider of communications and IT services. Its foundations date back to 1904 when Hull’s local authority established its own telephone network and it is the reason Hull is the only city in the UK where BT does not operate. KCOM was owned entirely by Hull City Council until its flotation on the London Stock Exchange in 1999 and in August 2019 it was acquired for £627m by Macquarie European Infrastructure Fund 6, an investment fund managed by Macquarie Infrastructure and Real Assets (MIRA). The company has a long history of innovation. It installed the first all-digital telephone network in Europe and launched the first commercial broadband service in the UK. It also introduced the UK’s first online TV service in 1999, pre-empting today’s streaming and downloading technology by decades. Today KCOM provides broadband and phone services to more than 140,000 consumers and businesses in Hull and East Yorkshire while its national arm provides connectivity and IT services to public and private sector organisations across the UK. www.kcom.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye